The current financial score of Ovid Therapeutics Inc is 6.07. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 733.00K, representing a year-over-year decrease of 88.31%, while its net profit experienced a year-over-year decrease of 220.43%.
The current valuation score of Ovid Therapeutics Inc is 8.64. Its current P/E ratio is -11.51, which is -94.89% below the recent high of -0.59 and -17.43% above the recent low of -13.51.
The current earnings forecast score of Ovid Therapeutics Inc is 9.00. The average price target is 6.00, with a high of 9.00 and a low of 4.00.
The current price momentum score of Ovid Therapeutics Inc is 3.99. Currently, the stock price is trading between the resistance level at 2.83 and the support level at 2.28, making it suitable for range-bound swing trading.
The current institutional shareholding score of Ovid Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 39.21%, representing a quarter-over-quarter increase of 16.68%. The largest institutional shareholder is James Simons, holding a total of 105.50K shares, representing 0.00% of shares outstanding, with 19.05% decrease in holdings.
The current risk assessment score of Ovid Therapeutics Inc is 4.98. The company's beta value is 0.17. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.